Daily Literature Update
Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors related intracerebral hemorrhage in veterans
Rech MA, Budde E, Evans CT, et al. Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans. Am J Emerg Med. 2025 Jul;97:97-102. doi: 10.1016/j.ajem.2025.07.037. PMID:40700941.
Study Type: National retrospective cohort study within the Veteran Health Administration (2018–2024)
Population: Veterans with factor Xa inhibitor-related intracerebral hemorrhage (n=350 on fXa inhibitors; AA n=129, 4F-PCC n=221)
Intervention: Andexanet alfa (AA) versus 4-factor prothrombin complex concentrate (4F-PCC) for reversal
Outcomes: Primary effectiveness: 90-day mortality; Primary safety: 30-day thrombotic events (venous thromboembolism, pulmonary embolism, acute ischemic stroke, myocardial infarction) validated by manual chart review
Key Findings
- No significant difference in 90-day mortality: AA 30.9% vs 4F-PCC 36.6% (p=0.35)
- Significantly higher 30-day thrombotic events with AA (11.4%) vs 4F-PCC (2.4%) (p<0.01)
- Acute ischemic stroke particularly more common in AA group
- AA group more likely on apixaban (87.8% vs 77.2%, p=0.03) in matched cohort
Context & Related Research
- Systematic review/meta-analysis: No mortality difference but higher thrombotic events with AA vs 4F-PCC (PMID:39379749)
- ASTRO-DE prospective study, 2023: AA reduced hematoma expansion but increased thromboembolic risk (PMID:39834067)
- Several observational studies: Consistently highlight thrombotic risks with AA in factor Xa inhibitor-related ICH reversal
- Guidelines: Urge careful balancing of bleeding vs thrombotic risks when selecting reversal agents
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Large national veteran cohort with manual validation of thrombotic events | Retrospective design; potential for residual confounding despite propensity matching |
| Propensity score matching for demographic and clinical balance | Limited generalizability beyond predominantly male veteran population |
| Focused on clinically relevant safety endpoints with chart review | Potential coding inaccuracies and treatment selection bias |
Clinical Implications & Impact
Pharmacists should carefully assess thrombotic risk when recommending reversal agents for factor Xa inhibitor-associated ICH, recognizing that andexanet alfa may increase 30-day thrombotic events, especially acute ischemic stroke, without survival benefit over 4F-PCC. Collaborative risk-benefit discussions with multidisciplinary teams and vigilant monitoring for thrombosis in patients receiving AA are essential.
Conclusion
In veterans with factor Xa inhibitor-related intracerebral hemorrhage, andexanet alfa did not reduce 90-day mortality compared to four-factor prothrombin complex concentrate but was associated with a significantly higher rate of 30-day thrombotic events, particularly acute ischemic stroke.
Listen to the Podcast
A short discussion of today’s highlight.
Citations
- Rech MA et al. Am J Emerg Med. 2025 Jul;97:97-102. PMID:40700941
- Yahn BA et al. Systematic review/meta-analysis on AA vs 4F-PCC. 2023; PMID:39379749
- Meinel T et al. ASTRO-DE prospective study. 2023; PMID:39834067
- Additional observational studies on thrombotic risk with andexanet alfa, various years.
